John M. Leonard
Board Member
Intellia Therapeutics, Inc. (NTLA)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About John M. Leonard
John M. Leonard is recorded as Board Member at Intellia Therapeutics, Inc. (NTLA). Intellia Therapeutics, Inc. reported in an 8-K filed June 12, 2025 that John M. Leonard was appointed class III director, effective June 11, 2025. The proxy statement of Intellia Therapeutics, Inc. reports total compensation of $5,063,899 for John M. Leonard in fiscal 2025, including a base salary of $708,000. Disclosed compensation is on record for 9 fiscal years.
“The stockholders of the Company elected each of William Chase, Georgia Keresty, Ph.D., M.P.H. and John M. Leonard, M.D., as a class III director, for a three-year term ending at the annual meeting of stockholders to be held in 2028 and until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-06-11–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Intellia Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Edward J. Dulac III CFO
- Andrew D. Schiermeier COO
- James Basta General Counsel
- Michael P. Dube Chief Accounting Officer
- Bill Chase Board Member
- Brian Goff Board Member
- Georgia Keresty Board Member
- Georgia Keresty, Ph.D., M.P.H. Board Member
- John M. Leonard, M.D. Board Member
- Muna Bhanji Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Intellia Therapeutics, Inc. (NTLA) | President, Chief Executive Officer | $708,000 | $5,063,899 |
| 2024 | Intellia Therapeutics, Inc. (NTLA) | President, Chief Executive Officer | $687,000 | $15,330,547 |
| 2023 | Intellia Therapeutics, Inc. (NTLA) | President, Chief Executive Officer | $660,000 | $11,657,262 |
| 2022 | Intellia Therapeutics, Inc. (NTLA) | President, Chief Executive Officer | $630,000 | $10,096,590 |
| 2021 | Intellia Therapeutics, Inc. (NTLA) | President, Chief Executive Officer | $600,000 | $9,773,560 |
| 2020 | Intellia Therapeutics, Inc. (NTLA) | President, Chief Executive Officer | $580,000 | $3,635,676 |
| 2019 | Intellia Therapeutics, Inc. (NTLA) | President, Chief Executive Officer | $559,200 | $903,786 |
| 2018 | Intellia Therapeutics, Inc. (NTLA) | President, Chief Executive Officer | $550,000 | $9,708,330 |
| 2017 | Intellia Therapeutics, Inc. (NTLA) | President, Chief Executive Officer | $395,833 | $2,592,874 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.